Literature DB >> 11289131

Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling.

N Maestre1, T R Tritton, G Laurent, J P Jaffrézou.   

Abstract

Anthracyclines are, above all, DNA intercalators, which induce genetic damage leading to cell death. However, increasing evidence firmly suggests that the underlying mechanism for anthracycline cytotoxicity is the induction of apoptosis through intracellular-mediated signaling pathways. Whether drug/DNA interaction is necessary for such apoptosis signaling is unknown. We investigated the cellular effects of the anthracyclines daunorubicin (DNR) and doxorubicin (DOX) using the myeloid leukemia cell line U937. By comparing free drug against agarose bead-immobilized drug iDNR and iDOX (which cannot accumulate within the cell), we observed that whereas both free and immobilized anthracyclines were cytotoxic, only the former induced apoptosis; the latter induced necrosis. Indeed, we did not observe ceramide generation, neutral sphingomyelinase activation, poly (ADP-ribose) polymerase cleavage, or other apoptotic events with iDNR or iDOX. However, both free and immobilized drug were similarly capable of triggering nuclear factor kappaB activation. These observations demonstrate that whereas activation of certain cellular signaling pathways can be achieved solely through membrane interaction, apoptosis signaling requires anthracycline internalization. These results also show that the initiation of cell survival pathways (illustrated by nuclear factor kappaB activation) is independent of intracellular drug/target interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Novel agents for the treatment of childhood acute leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Ther Adv Hematol       Date:  2015-04

2.  Accumulated bending energy elicits neutral sphingomyelinase activity in human red blood cells.

Authors:  David J López; Meritxell Egido-Gabas; Iván López-Montero; Jon V Busto; Josefina Casas; Marie Garnier; Francisco Monroy; Banafshé Larijani; Félix M Goñi; Alicia Alonso
Journal:  Biophys J       Date:  2012-05-02       Impact factor: 4.033

3.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

4.  Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies.

Authors:  Chad A Corcoran; Qin He; Suriyan Ponnusamy; Besim Ogretmen; Ying Huang; M Saeed Sheikh
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

5.  Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells.

Authors:  A Malugin; P Kopecková; J Kopecek
Journal:  J Control Release       Date:  2007-08-23       Impact factor: 9.776

6.  Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.

Authors:  Kirsteen J Campbell; John M O'Shea; Neil D Perkins
Journal:  BMC Cancer       Date:  2006-04-21       Impact factor: 4.430

7.  A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.

Authors:  Matthew T McKenna; Jared A Weis; Stephanie L Barnes; Darren R Tyson; Michael I Miga; Vito Quaranta; Thomas E Yankeelov
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.